R.S. Douglas and Others
 |  |
Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition. In a randomized, double-masked, placebo-controlled, phase 3 multicenter trial, Douglas et al. investigated the efficacy and safety of teprotumumab, an insulin-like growth factor I receptor inhibitor, as compared with placebo in patients with clinically active thyroid eye disease.
No comments:
Post a Comment